

Patient number

Date of visit
month day year

BPH FORM F01.2

June, 1995

Page 1 of 4

FORM NUMBER = (FORM)
FORM VERSION = (VERS)

NIH - BPH TRIAL

STANDARD FOLLOW-UP VISIT INVENTORY

This form should be completed at all quarterly standard follow-up visits. At these visits, also complete AUA Symptom Questionnaire (Form Q01).

Part I / IDENTIFICATION

A. Patient Identification

1. Patient number (PATID)

clinic patient

2. Patient's initials (INITS)

first last

3. Patient's date of birth (DOB)

month day year

B. Visit Information

1. Date of visit (FVSTDT)

month day year

2. Week of visit (FVIWK)

Part II / VITAL SIGNS

C. Blood Pressure Readings

1. Supine Blood Pressure (After lying 5 minutes)

a. Blood Pressure Reading (FBPLS)/(FBPLD)

/ mmHg

b. Heart Rate (FBPLHR)

bpm

2. Standing Blood Pressure (Immediately)

a. Blood Pressure Reading 1 (FBPSS1)/(FBPSD1)

/ mmHg

b. Heart Rate 1 (FBPSHR1)

bpm

Wait 2 minutes

c. Blood Pressure Reading 2 (FBPSS2)/(FBPSD2)

/ mmHg

d. Heart Rate 2 (FBPSHR2)

bpm

Patient number

Date of visit
month day year

D. Orthostatic Hypotension

1. Did the patient have orthostatic hypotension? (**FORTHYP**)

YES NO

Orthostatic hypotension is defined as a decrease of more than 20mmHg in supine to standing systolic blood pressure or a decrease of more than 10mmHg in supine to standing diastolic blood pressure (in either standing blood pressure reading) or the development of significant postural hypotension.

Part III / MEDICATION DISPENSING AND COMPLIANCE AND ADVERSE EVENTS

E. Number of days since last visit (**FCDDAYS**)

F. Doxazosin Compliance

If doxazosin was dispensed at the last visit, returned and/or dispensed today, CONTINUE. If not, SKIP to Section G.

1. Dose of doxazosin (**FCDDOSE**)

1 mg 2 mg 4 mg 8 mg

2. Number of doxazosin tablets dispensed at the last visit (**FCDDISL**)

3. Number of doxazosin tablets returned today (**FCDRET**)

4. Compliance (**FCDCOMP**)

$$\frac{\text{tabs dispensed (\#2)} - \text{tabs returned (\#3)}}{\text{days since last visit (question E)}} \times 100$$

%

NOTE: Counsel patient if less than 80% compliant with doxazosin.

5. Number of doxazosin tablets dispensed today (**FCDDIST**)

G. Finasteride Compliance

If finasteride was dispensed at the last visit, returned and/or dispensed today, CONTINUE. If not, SKIP to Section H.

1. Number of finasteride tablets dispensed at the last visit (**FCFDISL**)

2. Number of finasteride tablets returned today (**FCFRET**)

3. Compliance (**FCFCOMP**)

$$\frac{\text{tabs dispensed (\#1)} - \text{tabs returned (\#2)}}{\text{days since last visit (question E)}} \times 100$$

%

NOTE: Counsel patient if less than 80% compliant with finasteride.

Patient number Date of visit
month day year

4. Number of finasteride tablets dispensed today (FCFDIST)

H. Concomitant Medications

1. Is the patient currently taking coded doxazosin? (FCDCODE)

YES	NO
<input type="text"/>	<input type="text"/>

2. Is the patient currently taking coded finasteride? (FCFCODE)

<input type="text"/>	<input type="text"/>
----------------------	----------------------

3. Is the patient currently taking any medication other than the coded medications? (FCMCON)

<input type="text"/>	<input type="text"/>
----------------------	----------------------

If YES, list below:

a.	(FCMCONA)	f.	(FCMCONF)
b.	(FCMCONB)	g.	(FCMCONG)
c.	(FCMCONC)	h.	(FCMCONH)
d.	(FCMCOND)	i.	(FCMCONI)
e.	(FCMCONJ)	j.	(FCMCONJ)

I. Adverse Events

1. Since the last scheduled follow-up visit, has the patient had any adverse experiences, drug reactions, side effects, abnormal laboratory values, hospitalizations, discontinued coded medications, other complications or pre-existing conditions that worsened? (FAELVST)

YES	NO
<input type="text"/>	<input type="text"/>

If YES, an Adverse Event Report (Form E04) MUST be completed.

Part IV / UROFLOW MEASUREMENTS AND PSA SPECIMEN

J. Uroflow Measurements

1. Voiding Time (FUMVT)

 sec

2. Flow Time (FUMFT)

 sec

3. Time to Maximum Flow (FUMTMF)

 sec

4. Maximum Flow Rate (FUMMXFR)

 ml/sec

5. Mean Flow Rate (FUMMNFR)

 ml/sec

6. Voided Volume (FUMVV)

 ml

7. Post Void Residual (FUMPVR)

 ml

Mark the date and patient number (either screening or study number) on each printout. Make two copies of the uroflow printout. One copy is filed with the source documents; the other along with the original printout is placed in the envelope in the patient's binder.

Patient number

Date of visit
month day year

K. PSA Serum Specimen

1. Is this a 6-month follow-up visit? (FPSA6MO) YES NO
1 2

If YES, serum should be drawn for PSA.

a. Date sent to the Diagnostic Center (FPSASDT)
month day year

Initials of person completing form (FORMIN)
first last

Form entered in computer? ☐

Signature of P.I. _____ Date _____